Revenue segments as reported by the company.

Net product sales

Collaboration revenue

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general, and administrative

Other operating (income) expense, net

Acquired in-process research and development

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Regeneron reports robust Q4 earnings, eyes strategic launches and collaborations

Regeneron Pharmaceuticals showcased strong financial performance and pipeline advancements in Q4 2022.
The company's focus on safety, efficacy, and strategic imperatives positions it for future growth.
Challenges include competitive positioning, trial data anticipation, and managing uncertainties.
Opportunities in market launches, accelerated approvals, and innovative collaborations drive future potential.

Regeneron excels in Q1 with strong revenue growth and pipeline advancements

Regeneron Pharmaceuticals delivered a strong performance in Q1 2023, driven by revenue growth and pipeline advancements in key therapeutic areas like DUPIXENT and EYLEA.
Despite operational challenges in market positioning and regulatory considerations, the company's strengths in research capabilities and strategic planning present growth opportunities.
With a focus on commercialization efforts, expanding indications, and leveraging genetic insights, Regeneron is poised to capitalize on opportunities for sustained success and innovation.
Navigating challenges in market competition and regulatory uncertainties, Regeneron remains proactive in addressing key issues to maintain its position as a leading biopharmaceutical company.

Regeneron reports strong Q2 earnings, eyes aflibercept launch

Regeneron Pharmaceuticals demonstrated strong financial performance and commercial success in Q2 2023.
While facing regulatory challenges, the company remains optimistic about pipeline advancements and potential launches.
Balancing efficacy and safety in treatments, Regeneron aims to capitalize on growth opportunities and strategic partnerships.
Robust cash position and focus on patient well-being position Regeneron for continued success and market expansion.

Regeneron posts robust Q3 results, eyes innovation and market growth

Regeneron's Q3 performance reflects strong revenue growth, financial stability, and promising market potential for key products like Dupixent and EYLEA HD.
While facing legal challenges and competitive pressures, the company's strategic focus on innovation, R&D, and shareholder value management positions it for long-term success.
With a robust pipeline, unique therapeutic targets, and a solid financial foundation, Regeneron is poised for continued growth, market leadership, and innovation in the biopharmaceutical industry.

Regeneron posts strong Q4 results, eyes growth through innovation

Regeneron Pharmaceuticals delivered a strong performance in Q4 2023, driven by successful product launches and financial results in line with expectations.
The company's focus on innovation, strategic leadership, and capital allocation priorities position them well for future growth and market success.
While facing challenges in market dynamics and competition, Regeneron has opportunities to leverage new product approvals and innovative treatment approaches.
Overall, Regeneron's performance highlights their resilience, strategic vision, and commitment to advancing healthcare through groundbreaking therapies.

Regeneron posts solid Q1 results, faces FDA request challenges

Regeneron Pharmaceuticals delivered strong financial performance in Q1 2024, driven by Dupixent and EYLEA HD.
The company's robust pipeline and focus on innovation position it well for future growth.
Challenges include FDA requests for Dupixent efficacy analyses and market entry hurdles for new products.
Opportunities lie in advancing therapies for COPD, severe food allergies, and expanding cancer treatment options.

Regeneron posts robust Q2 earnings, eyes pipeline expansion opportunities

Regeneron Pharmaceuticals demonstrated strong financial performance and product sales growth in Q2.
While facing regulatory challenges, the company's pipeline and market position remain robust.
Opportunities for expansion and innovation present avenues for future growth.
Overall, Regeneron's Q2 results reflect resilience and strategic focus.

Regeneron Pharmaceuticals reports strong Q3 results and eyes innovative growth

Regeneron's Q3 performance reflects solid revenue and earnings growth driven by key products. While facing regulatory challenges and capital allocation decisions, the company's focus on innovation and strategic investments positions it well for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

DRDGOLD

Vipshop Hlds

Investors target stocks that are witnessing a bullish run. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.

3 Stocks With Recent Price Strength Despite Market Turmoil

Buckle

Chipotle

Co-Diagnostics

Moderna

Trump floats financial aids to counter the impact of the coronavirus outbreak. Notable stimulus measures include payroll tax cut, aid for wage earners and an emergency funding worth $8.3 billion

5 Stocks to Win Big From Trump's Economic Stimulus

Applied Materials

Cardinal Health

eBay

KB Home

Lennar

PulteGroup

Western Digital

Despite the virus-driven global disturbance, the U.S. economy remains stable as indicated by recently released various data for the month of February.

How to Invest in a Volatile Market Amid a Stable U.S. Economy

Gilead Sciences

GlaxoSmithKline

Johnson & Johnson

Pfizer

Sanofi

7 Big Pharma Companies Trump Asked to Fight the Coronavirus Outbreak

DexCom

Can these winners in a losing market keep their momentum going?

3 Profitable Healthcare Stocks That Are Trouncing the Market During the Coronavirus Correction

Clorox

Campbell Soup

Kroger

Coronavirus worries are multiplying, but a few S&P 500 stocks are still in rally mode despite the stock market's jitters.

Here are the S&P 500 stocks that have outperformed since the Feb 20 peak

Regeneron (REGN) reported earnings 30 days ago. What's next for the stock?

Why Is Regeneron (REGN) Up 26.8% Since Last Earnings Report?

Cogent Communications Holdings

Iovance Biotherapeutics

Newmont Mining

iStar Inc

Virtu Financial

Vivint Smart Home Inc

The stock market in 2020 has gone from a raging bull market to panic mode in very short order.

10 Very Strong Stocks Thriving in a Very Crummy Stock Market

Century Communities

Coherus BioSciences

LGI Homes

QIAGEN

Investors target stocks that have been on a bullish run lately. Stocks seeing price strength have a high chance of carrying the momentum forward.

5 Stocks Trading Near 52-Week  High That Can Scale Higher.

The coronavirus is an immediate catalyst for Regeneron stock but it's also too unreliable to provide buyers with lasting confidence.
The post Regeneron Stock May Need More Than the Coronavirus appeared first on InvestorPlace.

Regeneron Stock May Need More Than the Coronavirus

Regeneron's (REGN) shares grow year to date owing to focus on developing a treatment for combating the novel coronavirus.

Regeneron (REGN) Gains from Focus on Coronavirus Treatments

Regeneron’s work on a coronavirus treatment gave the stock a lift.

Why Regeneron Shares Rose 31.6% in February

MSCI

Netflix

NVIDIA

Qorvo

Ralph Lauren

Here we discuss six S&P 500 stocks that are in the black despite the coronavirus scare.

6 Top-Ranked S&P 500 Stocks Ride Out the Coronavirus Rout

Inovio Pharmaceuticals

Novavax

Drug makers globally are working on developing therapies and vaccines for coronavirus. Here are five stocks that are currently in focus.

5 Drug Makers to Gain From Coronavirus Outbreak

Regeneron stock is one of the top names in the markets this year “thanks” to the coronavirus. But microbial threats down the line ensure that REGN is no flash in the pan.

Buy Regeneron Stock for Coronavirus 2.0 and Beyond

"How quickly that can be deployed will depend on some of the early data that we have, some animal data, what we will see in patients," Regeneron CEO Leonard Schleifer told CNBC.

Regeneron CEO hopes to have coronavirus treatment ready for human testing possibly by this summer

Vaxart

President Donald Trump asks pharmaceutical companies working on making vaccines or treatments for coronavirus to accelerate development.

Trump Asks Pharma Firms to Step Up Coronavirus Vaccine Work

American Airlines

Boeing

Chevron

Norwegian Cruise Line

Here're the big winners and losers since the coronavirus outbreak brought the U.S. bull market to a standstill.

Best & Worst Performing Stocks in Coronavirus Outbreak

Coronavirus work may give companies good press -- but resulting treatments won’t necessarily be a boon to earnings.

Here's Why Hype Around Companies Working on Coronavirus Treatments Is Overblown

Carnival

Live Nation

Royal Caribbean Cruises

Real Estate Select Sector SPDR Fund

Utilities Select Sector SPDR Fund

Investors had nowhere to hide this week. Following Thursday's stock market drubbing, there were just four S&P 500 companies trading in positive territory.

Cruise lines are big losers on Wall Street this week -- and there are few winners

Regeneron Pharmaceuticals shows improving price performance, earning an upgrade to its IBD Relative Strength Rating.
The post Stocks Showing Market Leadership: Regeneron Pharmaceutical Earns 93 RS Rating appeared first on Investor's Business Daily.

Stocks Showing Market Leadership: Regeneron Pharmaceutical Earns 93 RS Rating

As of late, it has definitely been a great time to be an investor in Regeneron Pharmaceuticals.

Will Regeneron Pharmaceuticals Continue to Surge Higher?

One's pain is another's gain, and this phrase ringed in true in the case of Regeneron Pharmaceuticals Inc (NASDAQ: REGN).

Regeneron Snags Upgrade On Reduced Prospects For Rival Eye Disorder Drug

Regeneron (REGN) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

Regeneron (REGN) Catches Eye: Stock Jumps 5.5%

News for Regeneron Pharmaceuticals Stock (REGN)